Abstract
Cetuximab (Erbitux) and panitumumab (Vectibix) are monoclonal antibodies to the EGFR. They are used as monotherapy or in combination with cytotoxic chemotherapy and increase both progression-free survival and overall survival in patients with wild-type RAS metastatic colorectal cancer. The most common side effects of therapy are dermatological, including skin (acneiform) rash, pruritus and hair changes. Despite their clinical activity, cost-effectiveness of the two drugs should be addressed in a discussion of their usage in everyday care. This study provides an up-to-date review of the clinical efficacy and cost-effectiveness of anti-EGFR inhibitors.
Keywords:
EGFR; cancer; cetuximab; colorectal; cost–effectiveness; panitumumab.
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / pharmacology
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Cetuximab
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / pathology
-
Cost-Benefit Analysis
-
Disease-Free Survival
-
ErbB Receptors / antagonists & inhibitors*
-
Humans
-
Panitumumab
-
Survival Rate
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Panitumumab
-
ErbB Receptors
-
Cetuximab